Evaluation of Adherence to Quality Measures for Prostate Cancer Radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey.

[1]  Heidi W Albright,et al.  Ensuring quality cancer care , 2012, Cancer.

[2]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[3]  S. Lipsitz,et al.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Movsas,et al.  Shifting the Focus to Practice Quality Improvement in Radiation Oncology , 2010, Journal for healthcare quality : official publication of the National Association for Healthcare Quality.

[5]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[7]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[8]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[10]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[11]  E. Emanuel,et al.  Patterns of care studies: creating "an environment of watchful concern". , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Grignon,et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Zelefsky,et al.  Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[15]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[16]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[17]  B. Bloom.  Crossing the Quality Chasm: A New Health System for the 21st Century , 2002 .

[18]  Alastair Baker,et al.  Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.

[19]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[20]  Joseph V. Simone,et al.  Enhancing Data Systems to Improve the Quality of Cancer Care , 2000 .

[21]  Thomas.  Over 20 Years of Progress in Radiation Oncology: Seminoma. , 1997, Seminars in radiation oncology.

[22]  Hanks,et al.  20 Years of Progress in Radiation Oncology: Prostate Cancer. , 1997, Seminars in radiation oncology.

[23]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[24]  L. Potters,et al.  Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. , 2005, Brachytherapy.

[25]  Eifel,et al.  20 Years of Progress in Radiation Oncology: Prostate Cancer. , 1997, Seminars in radiation oncology.